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http://dx.doi.org/10.1016/j.kjms.201Abstract The study aimed to evaluate the levels of serum free kappa (k) and lambda (l) light
chains in patients with rheumatoid arthritis (RA) as well as exploring the association between
serum free k and l light chains and activity of RA. For this purpose, healthy individuals and pa-
tients with active RA and RA in remission were enrolled, and their serum levels of free k and l
light chains were measured using rate nephelometry. The diagnostic accuracy of serum free k
and l light chains was evaluated by receiver operating characteristic curves and 95% confidence
intervals for areas under the curve (AUC). The results obtained indicated that the levels of serum
free k and l light chains in patients with active RAwere significantly higher than those of patients
in remission and of healthy controls (p< 0.05). Further, the AUC values in patients with active RA
were 0.871 for free k light chain and 0.781 for free l light chain. When the optimal cut-off point
for serum k light chain was 8.02 g/L, the maximum sensitivity and specificity were 82.5% and
82.5%, respectively, and when the optimal cut-off point for serum l light chain was 3.57 g/L,
themaximum sensitivity and specificity were 80% and 82.5%, respectively. It was thus found that
serum levels of free k and l light chainswere positively correlatedwith disease activity in RA, the
Disease Activity Score 28 (DAS28), and values for C-reactive protein (CRP), erythrocyte sedimen-
tation rate (ESR), platelet count (PLT), rheumatoid factor (RF), and anticitrullinated protein
antibody (ACPA) (p< 0.05). In conclusion, high serum levels of free k and l light chains in patients
with active RA are closely correlatedwith disease activity parameters including DAS28, CRP, ESR,
PLT, RF, and ACPA. Thus, the above-mentioned levels of serum free k and l light chains may be
used as important indicators of activity of RA.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.of Clinical Laboratory, The First Affiliated Hospital of Xi’an Medical University, No. 48, West Fenghao
(Y.-J. Li).
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with the 1987 American College of Rheumatology (ACR) clas-Rheumatoid arthritis (RA) is a chronic, systemic inflamma-
tory disorder that may affect many tissues and organs.
However, it principally attacks the synovial joints [1]. The
process produces an inflammatory response in the synovium
(synovitis) secondary to hyperplasia of the synovial cells as
well as excess synovial fluid. Further, it also leads to the
development of pannus in the synovium. The pathology of
the disease process often leads to destruction of the
articular cartilage and ankylosis of the joints [2]. RA can
also produce diffuse inflammation in the lungs, pericar-
dium, pleura, and sclera, as well as nodular lesions, most
common in the subcutaneous tissue under the skin [3].
Although the cause of RA is unknown, autoimmunity
plays a pivotal role in both its chronicity and progression.
Hence, RA is considered to be a systemic autoimmune dis-
ease. Infectious agents such as viruses, bacteria, and fungi
have long been suspected as potential causes of RA, but
none has been proven as the cause. Infections may trigger
activation of the immune system in susceptible individuals,
thereby leading to immune system disorders. Further, cy-
tokines are important in the pathologic procession of the
rheumatoid synovial lesion [4].
B cells are precursor cells that produce RA antibodies and
also play an important role in modulation of the immune
response. B cells are involved in the inflammatory reaction
and act as a bridge between the specific and nonspecific
immune responses [5]. Further, B cells migrate to the sy-
novial membrane in response to cytokine and B cell receptor
(BCR). The increase in the quantity of some cytokines can
further activate the B cells. It has been observed that the
number of plasma cells in patients with RA can maintain a
steady growth for several months, which indicates that the
chronic inflammation in the infected joints corresponds with
the persistent activation of the B cells [6].
Immunoglobulin consists of light chains and heavy chains.
The light chains include k and l types. Normal serum could be
the place to reserve the light chain, including some free light
chain. With overexpression of key genes involved in modula-
tion of the immune response, dysfunction of the T- and
B-lymphocytes is induced, with cloning secretion from the
plasma cell is increased, thereby leading to the production of
plenty of antibodies and free k and l light chains [7]. Thus, the
levels of free k and l light chains could reflect B cell activation
as well as being related to the progress of RA.
The serum k and l light chains are the focus of the present
experiment, in which 40 patients with RA in remission and 40
patients with active disease were selected. Analysis of cor-
relation with the activity of RA indicates that serum immu-
noglobulin k and l light chains could be used as biomarkers
for diagnosing the active period of RA.Materials and methods
Patients
In the present study, 80 patients with RA were successively
selecteddone from every two inpatients and outpatients at
the affiliated Hospital of Xi’an Medical College from January2008 to January 2010. This selection was made in accordance
sification criteria for RA [8]. The study protocol was approved
by the ethics committee at the institution. All patients and
healthy controls provided written informed consent.
Assessment of RA disease activity
According to the 1990 Disease Activity Score 28 (DAS28)
[9,10], higher scores along a range of 1 to 10 points suggest
higher disease activity. Calculations are made as follows:
(1) Tender joint count. Check 28 joints including the
proximal interphalangeal joints, metacarpophalangeal
joints, wrist, elbow, shoulder, and knee joints, and
then calculate the number of tender joints in the state
of joint tenderness or passive activity (T28).
(2) Swollen joint count. Check 28 joints as above and then
calculate the number of swollen joints (Sw28).
(3) Then apply the following equation: DAS28 Z [0.56 
sqrt(T28)þ 0.28 sqrt(SW28)þ 0.70 Ln(ESR)] 1.08þ
0.16, where ESR is erythrocyte sedimentation rate).
Case groups
The patients were divided into two groupsdthose with
active disease and those in remissiondin accordance with
the 1987 ACR classification criteria for RA. Forty patients
(10 male and female 30) with active RA were not being
treated with disease-modifying antirheumatic drugs. These
patients had an age range of 18e65 years, with a mean age
of 49  13 years, and a disease duration of 2 months to 16
years. In addition, 40 patients (12 male and 28 female) with
RA in remission were being treated with nonsteroidal anti-
inflammatory drugs, methotrexate, leflunomide, or
hydroxychloroquine. These patients had an age range of
19e68 years, with a mean age of 47  11 years, and a
disease duration of 6 months to 20 years. Comparisons were
made between the active and remission phases of RA. The
results demonstrate that the indicators of age, gender, and
disease duration were of no statistical significance.
Patients with other rheumatic diseases or heart, brain,
liver, kidney, hematopoietic system, and other serious dis-
eases were excluded. A total of 40 blood donors (14male and
26 female) were selected as the healthy control group by
conducting a physical examination at the affiliated Hospital
of Xi’an Medical College. These donors had an age range of
20e62 years, mean 43  11 years, and their age and gender
were matched with participants in the case group.
Clinical and laboratory parameters
The duration of morning stiffness, tender joint count,
swollen joint count, and values for C-reactive protein (CRP),
ESR, platelet count (PLT), anticitrullinated protein antibody
(ACPA), and rheumatoid factor (RF) were selected as the
parameters for researching test cases in clinical as well as
laboratory conditions. Applying the principles of rate neph-
elometry, serum free k and l chains were measured using a
BN ProSpec (Dade Behring Inc, USA) automatic special pro-
tein analyzer.
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Statistical analyses were performed with SPSS 11.5 soft-
ware (IBM SPSS Statistic, USA). The descriptive results of
continuous variables (age, body mass index, and duration of
morning stiffness) followed a normal distribution and were
presented as X  s. Comparisons between the two groups
were made using the paired-samples t test, while com-
parisons among the three groups were made using one-way
analysis of variance. ESR, CRP, RF, ACPA, and k and l values
followed a skewed distribution and were presented as
medians, and the statistical significance for intergroup
differences was assessed using the KruskaleWallis test;
pairwise comparison was carried out with the Man-
neWhitney U test. Nonparametric material was assessed
with the Pearson Chi-square test. Spearman correlation
analysis was used for assessing the relationship between
the serum free k and l light chains and other variables, with
p values <0.05 considered statistically significant.
Using the ACR classification standard as the gold stan-
dard, serum free k and l light chains and the sensitivity,
specificity, positive predictive value, negative predictive
value, the positive likelihood ratio, the negative likelihood
ratio, and Youden index (the diagnostic index for the active
period of RA) were compared. Receiver operator curves
(ROC) curves were drawn to determine the best fit for each
index critical value, and the area under the curve (AUC)
and 95% confidence interval (CI) were used to express the
overall efficiency of diagnosis.Results
Related parameters in active RA and in remission
It was found that the differences in age, weight, and
gender between the three groups were not statistically
significant (F Z 0.843 and 1.081 for age and weight
respectively; Chi-square Z 0.012; for gender; p > 0.05).Table 1 Comparison of baseline demographics and clinical and l
patients in remission, and healthy controls.
Characteristics Active phase (n Z 40) Remission (
Age (yr) 49  13# 47  11#
Female (n) 10 12
Body mass index (kg/m2) 24.63  3.7# 23.7  3.8#
Duration of morning
stiffness (min)
61  11a,# 10  4#
ESR (mm/h) 53 (22e109)a,b,* 18 (10e26)c
CRP (mg/L) 26.6 (3.3e60.0)a,b,* 3.6 (0.56e4
PLT (109/L) 363 (257e442)a,b,* 209 (176e2
RF (kIU/L) 96.7 (35.5e182)a,b,* 28.5 (10.3e
ACPA (kIU/L) 53.5 (35.6e481)a,b,* 20.9 (13.4e
DAS28 7.6  1.5a,# 1.6  0.3#
ACPA Z anticitrullinated protein antibody; CRP Z C-reactive protein
sedimentation rate; PLT Z platelet count; RF Z rheumatoid factor.
a p < 0.05, active phase vs. remission.
b p < 0.05 active phase vs. controls.
c p < 0.05 remission vs. controls.The duration of morning stiffness and DAS28 scores in the
active phase were significantly higher than those in patients
in remission (t Z 25.594 and 20.163, respectively;
p < 0.01).
Statistical significance for the intergroup differences
was assessed by the KruskaleWallis test. The related pa-
rameters of the RA patients with active disease, including
ESR, CRP, PLT, RF, and ACPA, were found to be significantly
higher than those in healthy controls and patients with RA
in remission (H Z 101.193, 60.902, 90.947, 100.856, and
106.032, respectively; p < 0.01).
Pairwise comparison was carried out using the Manne
Whitney U test. Levels of the above-mentioned parameters
werehigher in the active phase than inpatients in remission or
healthy controls (active phase compared with remission,
Z Z 7.251, 5.120, 7.541, 6.341, and5.709 for ESR,
CRP, PLT, RF, and ACPA, respectively; active phase compared
with the healthy controls, Z Z 7.704, 6.408, 7.701,
5.703, and 7.718, respectively; remission compared with
healthy controls, Z Z 6.752, 3.264, 5.295, 7.633,
7.723, respectively; p < 0.05) (Table 1).
Levels of serum free k and l light chains from
different disease phases
Statistical significance for the intergroup differences was
assessed by the KruskaleWallis test. The serum levels of
free k and l light chains in each group showed significant
differences (H Z 88.837 and 87.572, respectively;
p < 0.05).
Pairwise comparison was carried out using the Manne
Whitney U test. The levels of serum free k and l chains in
patients with active RA were found to be significantly
higher than in those in remission and healthy controls
(active phase compared with remission, Z Z 5.090 and
5.856, respectively; active phase compared with healthy
controls, Z Z 7.410 and 7.574, respectively; remission
compared with healthy controls, Z Z 7.068 and 7.237,
respectively; p < 0.05). However, the ratios of k:l wereaboratory data from patients with active rheumatoid arthritis,
n Z 40) Controls (n Z 40) Statistics p
43  11# F Z 0.843 0.68
14 Chi-square Z 0.012 0.91
23.7  3.8# F Z 1.081 0.37
0 t Z 25.594 <0.01
,* 5 (2e10)* H Z 101.193 <0.01
.8)c,* 0.85 (0.28e2.6)* H Z 60.902 <0.01
78)c,* 155 (116e180)* H Z 90.947 <0.01
36.8)c,* 5.2 (3.5e14.6)* H Z 100.856 <0.01
28.6)c,* 3.6 (2.2e7.6)* H Z 106.032 <0.01
0 t Z 20.163 <0.01
; DAS28 Z Disease Activity Score in 28 joints; ESR Z erythrocyte
# means  standard deviations; * medians (ranges).
Table 2 Serum free k and l chain levels and k:l ratio in patients with active rheumatoid arthritis, patients in remission, and
healthy controls.
Variable Active phase (n Z 40)* Remission (n Z 40)* Controls (n Z 40)* H p
k (g/L) 9.83 (2.98e11.84)a,b 4.15 (2.15e10.32)c 2.77 (1.68e3.64) 88.84 0.01
l (g/L) 5.38 (1.71e6.38)a,b 2.27 (1.41e5.51)c 1.53 (0.98e2.10) 87.57 0.01
k:l ratio 1.65 (1.49e2.38) 1.68 (1.51e2.42) 1.63 (1.53e2.45) 0.362 0.697
* medians (ranges).
a p < 0.05, active phase vs. remission.
b p < 0.05 active phase vs. controls.
c p < 0.05 remission vs. controls.
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p Z 0.696) (Table 2 and Figs. 1 and 2).
Diagnostic accuracy of serum free k and l light
chains in active disease
The ROC curves for evaluating the diagnostic efficiency of
serum k and l light chains demonstrated that the AUCs in
patients with active RA were 0.871 (95% CI 0.785e0.956) for
free k light chain and 0.781 (95% CI 0.667e0.896) for l light
chain. Further, when the optimal cut-off points determined
by the ROC curves for serum k and l were 8.02 g/L and
3.57 g/L, respectively, the maximum sensitivity and speci-
ficity were 82.5% (33/40) and 82.5% (33/40) for free k light
chain, and 80% (32/40) and 82.5% (33/40) for free l light
chain. In the present study, the ROC curves were also used
for predicting other parameters including positive predic-
tive value, negative predictive value, positive likelihood
ratio, negative likelihood ratio, accuracy, and AUC (95% CI).
These values are listed in Table 3 (see also Fig. 3).
Correlation between serum free k and l light chains
and other parameters in active RA
Linear correlation analysis was carried out to evaluate the
relationship between serum free k (g/l) and l (g/l) light
chains and DAS28 (score), CRP (mg/l), ESR (mm/h), PLT
(109/l), RF (KIU/l), and ACPA (KIU/l) values. The results
demonstrate that the above parameters were positively
correlated with serum free k light chain (r Z 0.774, 0.693,Figure 1. Serum levels of free k and l chain (g/L) in patients w
healthy controls.0.729, 0.682, 0.348, and 0.316, respectively; p < 0.05) and
l light chain (r Z 0.665, 0.634, 0.694, 0.658, 0.362, 0.434,
respectively; p < 0.05) (Fig. 4 and Table 4).Discussion
RA is the most common inflammatory joint disease and
significantly affects patients’ quality of life. In time, it also
leads to a substantial loss of joint functionality [11]. The
main feature of RA is hyperplasia of the synovial cells,
which leads to the formation of an invasive pannus. Pannus
expansion can promote the destruction of cartilage and
bone, thereby resulting in a loss of joint functionality [12].
The immunoglobulin light chains are the k and l types.
Normally, the light chains exist in two sections, one section
being stored in the plasmocytes. In general, the resultant
production speed of the light chain is 8 minutes greater
than that of the heavy chain. Thus, after the formation of
one monomolecule of the immunoglobulin, an excess of
light chain exists. The pool of free light chain in the plasma
cells is called the light chain library [13]. The newly syn-
thesized light chain appears in the light chain library,
thereby replacing the reserved light chain and assembling
into new immunoglobulin. Therefore, the normal serum
acts as another reserve and a certain amount of polyclonal
light chain is always available [14].
In autoimmune diseases, the overexpression of key
genes involved in regulation of the immune response cause
dysfunction of the T- and B-lymphocytes, along with
increased cloning secretion of the plasma cells andith active rheumatoid arthritis (RA), patients in remission, and
Figure 2. The k:l chain ratio in patients with active rheu-
matoid arthritis (RA), patients in remission, and healthy
controls.
Figure 3. Receiver operator curves of diagnostic parameters
for active rheumatoid arthritis. When the optimal cut-off point
for serum k light chain was 8.02 g/L, the maximum sensitivity
and specificity were 82.5% and 82.5%, respectively (area under
the curve 0.871, p < 0.01). However, when the optimal cut-off
point for serum l light chain was 3.57 g/L, the maximum
sensitivity and specificity were 80% and 82.5%, respectively
(area under the curve 0.781, p < 0.01).
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k and l light chains in the serum increases relatively
[15,16]. Moyes et al. [17] established that the CDR3 of the
k and l light chain genes in the synovial membrane was
longer, and they overexpressed in the inflammatory. Thus,
the increase in level of light chains is one of the crucial
factors in the pathologic progression of RA. In addition,
Gottenberg et al. [18] found that levels of the k and l light
chains had a strong relationship to activation of the B cells,
showing a positive correlation with B cell activation.
The activity of RA indicates the speed of development of
the illness. Thus, an evaluation of disease activity and
progression can successfully guide treatment of theTable 3 Comparison of the diagnostic efficiency of serum free
tients with active rheumatoid arthritis (RA).
Variable Optimal
cut-off
point
Diagnostic efficiency of param
Specificity
(%)
Sensitivity
(%)
Positive
predictive
value (%)
Negative
predictive
value (%)
k (g/l) 8.02 82.5 82.5 82.5 82.5
l (g/l) 3.57 82.5 80 82.5 80
DAS28
(score)
3.30 87.5 90 87.8 87.7
ACPA
(KIU/l)
33.5 85 80.5 88.9 81.3
CRP
(mg/l)
25.1 70 70 70 72.5
ESR
(mm/h)
45 57.5 65 65 57.5
PLT
(109/l)
319 60 60 60 65
RF (KIU/l) 60 57.5 67.5 67.5 57.5
ACPAZ anticitrullinated protein antibody; AUCZ area under the curv
joints; ESR Z erythrocyte sedimentation rate; PLT Z platelet count;disease. DAS28 is an evaluation criterion that is based on
the number of swollen joints and on experimental indexes.
These factors present an objective assessment of disease
activity. In the late 1990s, research conducted in Italy [19]
confirmed that DAS28 is the best standard for defining the
activity of RA. At present, clinicians have combined DAS28
scores with CRP, ESR, ACPA, RF, and PLT values for judging
disease activity in RA [20,21]. Through an analysis of the
correlation between the serum free k and l light chains and
the activity index of RA, the present study confirmed thatk and l light chains with other diagnostic parameters in pa-
eters in patients with RA AUC (95% CI)
Positive
likelihood
ratio
Negative
likelihood
ratio
Youden
Index
Accuracy
(%)
4.71 0.21 0.65 82.5 0.871 (0.785e0.956)
4.49 0.24 0.63 81.3 0.781 (0.737e0.926)
7.2 0.11 0.77 90.4 0.932 (0.894e0.991)
4.36 0.18 0.66 82.8 0.851 (0.792e0.957)
2.45 0.39 0.40 71.3 0.763 (0.707e0.892)
1.60 0.64 0.23 61.3 0.615 (0.516e0.753)
1.66 0.59 0.20 62.5 0.623 (0.522e0.767)
1.70 0.58 0.25 62.5 0.581 (0.473e0.725)
e; CRPZ C-reactive protein; DAS28Z Disease Activity Score in 28
RF Z rheumatoid factor.
Figure 4. Analysis of correlation between serum free k (A) and l (B) light chains and Disease Activity Score 28 (DAS28). Linear
correlation analysis shows that serum free k and l light chain levels were positively correlated with DAS28 score in patients with
active rheumatoid arthritis (r Z 0.774 and 0.665, respectively; p < 0.05).
552 Y. Ye et al.serum levels of free k and l light chains increased in close
relation to the disease activity index (p < 0.05).
In the present study, it was observed that the serum
levels of k and l light chains in normal controls were low,
while levels in patients were significantly higher. Levels of
serum k and l light chains were particularly elevated in the
active phase of RA (p < 0.05). However, the difference in
the k:l ratio between the groups was not statistically sig-
nificant. The results obtained indicated that RA is a poly-
clonal proliferation disease. According to the ROC curve of
the serum k and l light chains, it was observed that the AUC
of serum k and l light chains used to diagnose RA was 0.871
and 0.781, respectively. When the k light chain level was
8.02 g/L, the diagnostic sensitivity for active RA was 82.5%
and the specificity was 82.5%; when the l light chain level
was 3.57 g/L, the diagnostic sensitivity for active RA was
80% and the specificity 82.5%. Linear correlation analysis
was used to evaluate the relationship between the serum
free k and l light chains and DAS28, CRP, ESR, PLT, RA, and
ACPA values. The results demonstrated that serum free
k and l light chain levels were positively correlated with
the above parameters. The analysis of the relevance of
serum free k and l light chains for activity of RA indicatesTable 4 Analysis of correlation between serum free k and
l light chains and other parameters for patients with active
rheumatoid arthritis.
Variable Serum free k chains Serum free l chains
r p r p
DAS28 0.774 0.01 0.665 0.01
CRP (mg/L) 0.693 0.01 0.634 0.01
ACPA (kIU/L) 0.729 0.01 0.694 0.01
ESR (mm/h) 0.682 0.01 0.658 0.01
PLT (109/L) 0.348 0.028 0.362 0.02
RF (kIU/L) 0.316 0.047 0.434 0.036
ACPA Z anticitrullinated protein antibody; CRP Z C-reactive
protein; DAS28 Z Disease Activity Score in 28 joints;
ESR Z erythrocyte sedimentation rate; PLT Z platelet count;
RF Z rheumatoid factor.that serum free k and l light chains values combined with
DAS28, CRP, and ESR could be used for the early diagnosis of
active RA. Thus, serum free k and l light chains can be used
as a simple and fast experimental index in the differential
diagnosis of disease activity and paracmasia in RA patients.
In conclusion, the results obtained demonstrated that
the serum k and l light chains are important inflammatory
indexes and may be used as indicators of disease activity
in RA.
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